| CAS NO: | 173334-58-2 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 609.83 |
|---|---|
| Formula | C30H53N3O6.1/2C4H4O4 |
| CAS No. | 173334-58-2 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (164.0 mM) |
| Water: 100 mg/mL (164.0 mM) | |
| Ethanol: 100 mg/mL (164.0 mM) | |
| Other info | Chemical Name: (αS,γS,δS,ζS)-δ-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-γ-hydroxy-4-methoxy-3-(3-methoxypropoxy)-α,ζ-bis(1-methylethyl)-benzeneoctanamide, 2E-butenedioate InChi Key: KLRSDBSKUSSCGU-KRQUFFFQSA-N InChi Code: InChI=1S/2C30H53N3O6.C4H4O4/c2*1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;5-3(6)1-2-4(7)8/h2*10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);1-2H,(H,5,6)(H,7,8) SMILES Code: COC1=C(OCCCOC)C=C(C[C@H](C(C)C)C[C@H](N)[C@@H](O)C[C@H](C(NCC(C)(C)C(N)=O)=O)C(C)C)C=C1.OC(/C=C/C(O)=O)=O |
| Synonyms | CGP060536B; SPP-100; CGP 060536B; SPP 100; CGP-060536B; Rasilez; SPP100; Tekturna |
| In Vitro | In vitro activity: Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans. |
|---|---|
| In Vivo | Aliskiren hemifumarate (< 10 mg/kg, oral) inhibits plasma renin activity and lowers blood pressure in sodium-depleted marmosets. Once-daily oral treatment with Aliskiren hemifumarate lowers blood pressure effectively, with a safety and tolerability profile, in patients with mild-to-moderate hypertension. |
| Animal model | |
| Formulation & Dosage | < 10 mg/kg, oral |
| References | Pharmacol Rep. 2008 Sep-Oct;60(5):623-31; Biochem Biophys Res Commun. 2003 Sep 5;308(4):698-705. |
m.cnreagent.com